Artivion, Inc. (NYSE:AORT) Insider John E. Davis Sells 15,100 Shares

Artivion, Inc. (NYSE:AORT - Get Free Report) insider John E. Davis sold 15,100 shares of Artivion stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total value of $356,511.00. Following the sale, the insider now directly owns 208,778 shares in the company, valued at $4,929,248.58. The trade was a 6.74 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Artivion Trading Up 3.1 %

Shares of AORT stock traded up $0.73 on Friday, reaching $24.15. 366,184 shares of the stock were exchanged, compared to its average volume of 259,302. The stock has a market cap of $1.02 billion, a PE ratio of -1,207.25 and a beta of 1.79. Artivion, Inc. has a one year low of $19.36 and a one year high of $32.33. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The stock has a 50 day moving average price of $28.66 and a 200 day moving average price of $27.73.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.51). The company had revenue of $97.31 million for the quarter, compared to analyst estimates of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. Equities research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Remove Ads

Analyst Ratings Changes

Several equities research analysts have issued reports on AORT shares. JMP Securities reissued a "market outperform" rating and issued a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Stifel Nicolaus dropped their price target on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Finally, Needham & Company LLC decreased their price objective on Artivion from $34.00 to $32.00 and set a "buy" rating on the stock in a report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $31.40.

Hedge Funds Weigh In On Artivion

Several institutional investors have recently modified their holdings of AORT. Smartleaf Asset Management LLC raised its holdings in Artivion by 236.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock worth $32,000 after buying an additional 786 shares during the period. Quarry LP boosted its stake in Artivion by 210.8% in the 3rd quarter. Quarry LP now owns 1,209 shares of the company's stock worth $32,000 after purchasing an additional 820 shares during the period. R Squared Ltd bought a new position in Artivion during the 4th quarter worth about $39,000. Arcadia Investment Management Corp MI acquired a new stake in shares of Artivion in the 4th quarter valued at about $43,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Artivion in the fourth quarter valued at about $64,000. Institutional investors own 86.37% of the company's stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.